Australia at BIO 2007
Tuesday, 03 April, 2007
Australians will be out in force at BIO 2007, the world's largest convention for the biotech industry, and Australian Life Scientist will be there, in print and in person.
In our March/April issue, we take an in-depth look at who is doing what in biotechnology from all corners of the country, concentrating on the science as well as the share price.
Australia's biotechnology sector seems to have got over last year's little hump and is powering forward. We take an in-depth look at who's doing what in Australian biotech, including profiles of Apollo Life Sciences, Clinuvel, PaleoTechnology International, Stirling Products, Marinova, Bionomics and Progen.
We also talk to leading figures from research provider CSIRO, pharma giant Merck Sharpe & Dohme and clinical trials specialists Nucleus Network and Q-Pharm.
In addition to our 30-page BIO 2007 preview, we take a look at the latest research from Australian scientists, what's happening in RNAi and technological developments in proteomics. We also speak to Dr Megan Munsie, the new policy director at the Australian Stem Cell Centre.
Stem cells Legislation allowing therapeutic cloning was passed last year, but only becomes legal on June 12. What comes next for embryonic stem cell research in Australia?
Research The stem cell theory of cancer; alleles influencing eye, hair and skin colour; and genetics, immunity and inflammatory bowel disease.
Proteomics High-throughput protein analysis takes a closer look at the molecular and cellular basis of prostate cancer; and characterising glycans in human breast milk.
RNAi In vivo use of RNAi for cervical cancer; RNA, microRNAs and human disease; DNA-directed RNAi; and siRNAs and off-target effects.
PLUS All the latest products on the market in Lab News, all the latest titles on the market in Bookshop and all the latest conferences on the calendar in Events.
If you would like a free copy of the March/April issue of ALS or a subscription form, please email kate_mcdonald@idg.com.au with your postal address. Alternatively, if you would like a digital copy, please email kate_mcdonald@idg.com.au Warning - the digital file size is over 4Mb
Towards the next generation of vision implants
An ultrasmall implant, with electrodes the size of a single neuron that can remain intact in the...
One-two punch treatment knocks out acute myeloid leukaemia
Researchers paired venetoclax, a current standard-of-care anticancer drug for acute myeloid...
Researchers find the 'switch' that deactivates brown fat
Researchers have found a protein that is responsible for turning off brown fat activity, in a...
